GLP-1R polymorphism (rs1042044) and expression are associated with the risk of papillary thyroid cancer among the Egyptian population

• Published in: Gene 2022-08, Vol.834, p.146597-146597, Article 146597
• Main Authors: Abdul-Maksoud, Rehab S., Elsayed, Walid S.H., Rashad, Nearmeen M., Elsayed, Rasha S., Elshorbagy, Shereen, Hamed, Mohamed G.
• Format: Article
• Language: English
• Subjects: Expression; GLP-1R; Polymorphism; PTC
• ISSN: 0378-1119; 1879-0038
• DOI: 10.1016/j.gene.2022.146597

•The rs1042044 C > A polymorphism may influence PTC risk and invasion by affecting GLP-1R expression.•Upregulation of GLP-1R expression was correlated with prognostic markers in PTC patients.•GLP-1R mRNA expression analysis could diagnose PTC with 95% sensitivity and 97% specificity.•The rs1042044 SNP and tissue GLP-1R expression might be employed as genetic markers for PTC incidence and invasion. Glucagon like peptide-1 receptor (GLP-1R) agonist usage has previously been linked to an elevated incidence of thyroid cell adenomas and carcinomas in animals. The goal of this study was to determine if there was an association between GLP-1R gene polymorphism and expression with the risk of papillary thyroid carcinoma (PTC) and its clinical characteristics among the Egyptian population. A total of eighty PTC patients and eighty healthy controls were included in the study. Real-time polymerase chain reaction (real-time PCR) and immunohistochemistry were used to determine GLP-1R expression in tumor tissue. The polymorphisms rs1042044 and rs6923761 in the GLP-1R gene were determined using PCR -restriction fragment length polymorphism (PCR-RFLP). PTC patients exhibited considerably greater frequencies of rs1042044 AA genotypes and A allele than controls (OR (95% CI) = 4.5 (1.75–11.8), P